The University of New Mexico

Loyola University of Chicago

University of London

Durvasula, Ravi

Kang, Angray Singh

Markiv, Anatoliy

Ravi Durvasula

Adinarayana Kunamneni

Karin Westlund High

Ivy Foo-Hurwitz

Anatoliy Markiv

Scott Matthews

Angray Singh Kang

Steven Bradfute

Michael Workman

A composition for treating pain includes an antibody or antibody fragment that specifically binds to a receptor involved in pain. In some embodiments, the receptor is a P2X family receptor such as, for example, P2X4. In some embodiments, the antibody includes a detectable marker. In some of these embodiments, the detectable marker includes a fluorescent tag. The composition may be used to treat acute or chronic pain in a subject. Generally, the methods includes administering to the subject a composition that includes an antibody or antibody fragment that specifically binds to a receptor involved in pain. The non-opioid pain relief composition can reverse pain related mechanical, cold, anxiety-like, and depression-like behaviors in neuropathic pain and chemotoxic nerve injury models.

Compositions comprising antibodies or antibody fragments which bind the P2X4 receptor

An antibody that binds to a filovirus glycoprotein generally includes include a complementarity determining region (CDR) of any one of SEQ ID NO:27-36 or a combination of such CDRs. The antibody may be used in to detect filovirus in a biological sample obtained from a subject. The antibody also may be formulated into a pharmaceutical composition for administering to a subject having, or at risk of having, a filovirus infection.

Filovirus antibodies and methods

A pharmaceutical composition generally includes a therapeutic antibody, or fragment thereof, and a pharmaceutically acceptable carrier. The therapeutic antibody specifically binds to a target peptide that mediates pain in a subject. The composition may be administered to a subject experiencing pain to at least partially alleviate the pain.

Therapeutic antibody fragments, methods of making, and methods of use

A larvicide comprising an essential oil encapsulated within a non-viable yeast cell. The larvicide is particularly effective against mosquito larvae, non-toxic to humans and other non-target species, inexpensive to make, and non-toxic during manufacture, transport, and storage.

Non-toxic larvicide

An larvicide comprising an essential oil encapsulated within a non-viable yeast cell. The larvicide is particularly effective against mosquito larvae, non-toxic to humans and other non-target species, inexpensive to make, and non-toxic during manufacture, transport, and storage.

Embodiments of the present invention provide for the facile generation of a stable recombinant fusion polypeptides with intrinsic fluorescent properties. The recombinant antibodies may be suitable for qualitative and/or quantitative immunofluorescence analysis. Generally, the fluorescent polypeptides include a fluorescent domain comprising a C-terminus and an N-terminus; a first antibody domain covalently linked to the C-terminus; and a second antibody domain covalently linked to the N-terminus.

Growing community of inventors

Albuquerque, NM, United States of America

Ravi Durvasula